Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thierry Facon

Showing results (31-40 of 301) with videos related to

Pageof 31
Sort By:
Haematologica|January 12, 2005
Factors predicting molecular and cytogenetic response in chronic myeloid leukemia patients treated with imatinibCatherine Roche-Lestienne, Stéphane Darré, Jean-Luc Laï, et al.
Presse Medicale (Paris, France : 1983)|August 27, 2019
[Multiple myeloma: New criteria for diagnosis and treatment, strong therapeutic hopes]Salomon Manier, Marie de Charette de la Contrie, Julia Hieulle, et al.
Blood Reviews|February 8, 2022
Current state and next-generation CAR-T cells in multiple myelomaSalomon Manier, Tiziano Ingegnere, Guillaume Escure, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 10, 2021
Association of Morbid Progression With Overall Survival Among Patients With Multiple Myeloma: Validation of the Progression-free Survival EndpointAaron S Rosenberg, Thierry Facon, Kejal Parikh, et al.
Blood Advances|August 5, 2021
Effective anti-BCMA retreatment in multiple myelomaNicolas Gazeau, David Beauvais, Ibrahim Yakoub-Agha, et al.
Joint Bone Spine|November 6, 2007
Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapyMarie-Hélène Vieillard, Jean-Michel Maes, Guillaume Penel, et al.
Expert Review of Hematology|October 1, 2014
Pomalidomide for multiple myelomaGuillemette Fouquet, Claire Bories, Stéphanie Guidez, et al.
Cancer Treatment and Research|October 4, 2016
Treatment of Newly Diagnosed Elderly Multiple MyelomaGuillemette Fouquet, Francesca Gay, Eileen Boyle, et al.
Leukemia & Lymphoma|June 24, 2017
Long-term health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma receiving lenalidomide and dexamethasoneDan T Vogl, Michel Delforge, Kevin Song, et al.
Blood|August 15, 2002
Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapyPhilippe Moreau, Thierry Facon, Xavier Leleu, et al.
Pageof 31

Showing results (31-40 of 301) with videos related to

Sort By:
Pageof 31
Haematologica|January 12, 2005
Factors predicting molecular and cytogenetic response in chronic myeloid leukemia patients treated with imatinibCatherine Roche-Lestienne, Stéphane Darré, Jean-Luc Laï, et al.
Presse Medicale (Paris, France : 1983)|August 27, 2019
[Multiple myeloma: New criteria for diagnosis and treatment, strong therapeutic hopes]Salomon Manier, Marie de Charette de la Contrie, Julia Hieulle, et al.
Blood Reviews|February 8, 2022
Current state and next-generation CAR-T cells in multiple myelomaSalomon Manier, Tiziano Ingegnere, Guillaume Escure, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 10, 2021
Association of Morbid Progression With Overall Survival Among Patients With Multiple Myeloma: Validation of the Progression-free Survival EndpointAaron S Rosenberg, Thierry Facon, Kejal Parikh, et al.
Blood Advances|August 5, 2021
Effective anti-BCMA retreatment in multiple myelomaNicolas Gazeau, David Beauvais, Ibrahim Yakoub-Agha, et al.
Joint Bone Spine|November 6, 2007
Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapyMarie-Hélène Vieillard, Jean-Michel Maes, Guillaume Penel, et al.
Expert Review of Hematology|October 1, 2014
Pomalidomide for multiple myelomaGuillemette Fouquet, Claire Bories, Stéphanie Guidez, et al.
Cancer Treatment and Research|October 4, 2016
Treatment of Newly Diagnosed Elderly Multiple MyelomaGuillemette Fouquet, Francesca Gay, Eileen Boyle, et al.
Leukemia & Lymphoma|June 24, 2017
Long-term health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma receiving lenalidomide and dexamethasoneDan T Vogl, Michel Delforge, Kevin Song, et al.
Blood|August 15, 2002
Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapyPhilippe Moreau, Thierry Facon, Xavier Leleu, et al.
Pageof 31